22
Participants
Start Date
December 1, 2021
Primary Completion Date
December 1, 2022
Study Completion Date
December 1, 2024
T cell injection targeting CD7 chimeric antigen receptor
The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 0.5 × 106, 2.0 × 106 and 4.0 × 106 CAR-T/kg groups in order of sequence. And the subjects will be administered once.
RECRUITING
PersonGen.Anke Cellular Therapeutice Co., Ltd., Hefei
Lead Sponsor
The First Affiliated Hospital of Zhengzhou University
OTHER
Peking University People's Hospital
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)
UNKNOWN
Zhejiang University
OTHER
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
INDUSTRY